Atherosclerotic cardiovascular disease has been the subject of sustained clinical investigation across multiple research sites.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID	Title	Status	Phase
NCT05485961	Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	RECRUITING	—
NCT07037433	Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity	RECRUITING	—
NCT07037433	Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity	RECRUITING	—
NCT05378529	A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)	COMPLETED	NA
NCT05485961	Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	RECRUITING	—
NCT05581303	Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial	ACTIVE_NOT_RECRUITING	PHASE3
NCT01663402	ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab	COMPLETED	PHASE3
NCT05485961	Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	RECRUITING	—
NCT07037433	Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity	RECRUITING	—
NCT05485961	Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	RECRUITING	—

Related Pages

All Atherosclerotic cardiovascular disease trials All trials in London, United Kingdom